Modified bovine g-csf polypeptides and their uses

Patent metadata

Field	Value
Publication number	US-2023348547-A1
Application number	US-202218087045-A
Country	US
Kind code	A1
Filing date	Dec 22, 2022
Priority date	Jul 23, 2008
Publication date	Nov 2, 2023
Grant date	—

Abstract

Modified bovine G-CSF polypeptides and uses thereof are provided.

First claim

What is claimed is:

1 - 53 . (canceled)

54 . An isolated nucleic acid comprising a polynucleotide that hybridizes under stringent conditions to SEQ ID NO: 3 or 4 or a polynucleotide sequence encoding SEQ ID NO: 1 or 2, wherein the polynucleotide comprises at least one selector codon.

55 . The isolated nucleic acid of claim 54 , wherein the selector codon is selected from the group consisting of an amber codon, ochre codon, opal codon, a unique codon, a rare codon, and a four-base codon.

56 - 68 . (canceled)

69 . A cell comprising the nucleic acid of claim 54 .

70 . (canceled)

71 . A method of making a bG-CSF polypeptide comprising a non-naturally encoded amino acid, the method comprising, culturing cells comprising a polynucleotide or polynucleotides encoding a bG-CSF polypeptide comprising a selector codon, an orthogonal RNA synthetase and an orthogonal tRNA under conditions to permit expression of the bG-CSF polypeptide comprising a non-naturally encoded amino acid; and purifying the bG-CSF polypeptide.

72 - 104 . (canceled)

105 . The isolated nucleic acid of claim 54 , wherein the isolated nucleic acid comprising the polynucleotide sequence encoding SEQ ID NO: 1.

106 . The isolated nucleic acid of claim 105 , wherein position 133 of SEQ ID NO: 1 is substituted with a non-naturally encoded amino acid.

107 . The isolated nucleic acid of claim 106 , wherein the non-naturally encoded amino acid is para-acetylphenylalanine.

108 . The isolated nucleic acid of claim 106 , wherein the non-naturally encoded amino acid is linked to a water soluble polymer comprising a poly(ethylene) glycol moiety.

109 . The isolated nucleic acid of claim 54 , wherein the isolated nucleic acid comprising the polynucleotide sequence encoding SEQ ID NO: 2.

110 . The isolated nucleic acid of claim 109 , wherein position 134 of SEQ ID NO: 2 is substituted with a non-naturally encoded amino acid.

111 . The isolated nucleic acid of claim 110 , wherein the non-naturally encoded amino acid is para-acetylphenylalanine.

112 . The isolated nucleic acid of claim 110 , wherein the non-naturally encoded amino acid is linked to a water soluble polymer comprising a poly(ethylene) glycol moiety.

113 . The method of claim 71 , wherein the isolated nucleic acid comprising the polynucleotide sequence encoding SEQ ID NO: 1.

114 . The method of claim 113 , wherein position 133 of SEQ ID NO: 1 is substituted with a non-naturally encoded amino acid.

115 . The method of claim 114 , wherein the non-naturally encoded amino acid is para-acetylphenylalanine.

116 . The method of claim 114 , wherein the non-naturally encoded amino acid is linked to a water soluble polymer comprising a poly(ethylene) glycol moiety.

117 . The method of claim 71 , wherein the isolated nucleic acid comprising the polynucleotide sequence encoding SEQ ID NO: 2.

118 . The method of claim 117 , wherein position 134 of SEQ ID NO: 2 is substituted with a non-naturally encoded amino acid.

119 . The method of claim 118 , wherein the non-naturally encoded amino acid is para-acetylphenylalanine.

120 . The method of claim 118 , wherein the non-naturally encoded amino acid is linked to a water soluble polymer comprising a poly(ethylene) glycol moiety.

Assignees

• Ambrx Inc
• Elanco Us Inc

Inventors

• Hays Putnam Anna-Maria A
• Knudsen Nick
• Norman Thea
• Koder Alan
• Kraynov Vadim
• Skidmore Lillian
• Canning Peter C

Classifications

• C07K14/535 Primary

  Granulocyte CSF; Granulocyte-macrophage CSF · CPC title

• A61K38/193

  Colony stimulating factors [CSF] · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P11/16

  Central respiratory analeptics · CPC title

• A61P15/14

  for lactation disorders, e.g. galactorrhoea · CPC title